-
U.S. P2Y12 Inhibitors Market Projected To Witness Substantial Growth, 2024-2031: Teva Pharmaceuticals USA, Cipla, Biocon
14 Nov 2024 10:13 GMT
…
◘ CHIESI USA Inc.
◘ Lupin
◘ Cipla
◘ Biocon
This Report includes a company … , product trials pipelines, product approvals, patents, product width and breath, application …
-
Type 1 Diabetes Market Detailed In New Research Report 2024 | Biocon Ltd., Novo Nordisk, Gan & Lee Pharmaceuticals
28 Oct 2024 06:04 GMT
… Players Covered In This Report:
◘ Biocon Ltd.
◘ Novo Nordisk
◘ Gan … , product trials pipelines, product approvals, patents, product width and breath, application …
-
Docs discuss sluggish switch to Humira biosimilars, name preferred off-patent options
24 Sep 2024 13:24 GMT
… market and their preferred off-patent options.
AbbVie reported global Humira … largely been driven to off-patent options by “external pressures.” Those … by Sandoz, Boehringer Ingelheim and Biocon, and Samsung Bioepis and Organon …
-
MOH Mandates Two Suppliers In Off-Patent Drugs, Medical Devices Procurement
23 Sep 2024 03:48 GMT
… single-PRH products involving off-patent drugs with only one supplier … supplied by Indian biosimilars company Biocon Biologics that operates Asia’s … attributed the insulin shortage to Biocon’s alleged failure to meet …
-
U.S. P2Y12 Inhibitors Market Set to Witness Significant Growth by 2024-2031: Panacea Biotec, Lupin, Cipla, Biocon
11 Sep 2024 10:44 GMT
… Adoption of Generic Versions: The patent expirations of major P2Y12 inhibitors …
◘ CHIESI USA Inc.
◘ Lupin
◘ Cipla
◘ Biocon
Deep-dive Analysis:
The Report …
-
Biocon Biologics signs agreement with Janssen to market Bmab 1200
29 Aug 2024 11:26 GMT
… biosimilar to Stelara (Ustekinumab).
Biocon plans to commercialise the … patent disputes between the parties and enables market entry for Biocon … 10.85bn in 2023.
Biocon Biologics CEO and managing … diseases.”
In May 2024, Biocon entered an exclusive licence …
-
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan
29 Aug 2024 11:08 GMT
… this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to … markets are currently under review.
Biocon Biologics earlier announced a settlement … Tambe, CEO & Managing Director, Biocon Biologics Ltd, said, “This settlement …
-
Biocon Biologics Inks Pact with JJ and Janssen Arms to Market ‘Bmab’ in Europe and Japan
29 Aug 2024 07:10 GMT
… and a subsidiary of Biocon Ltd, announced that it … biosimilar company has resolved patent disputes with Janssen to secure … & Managing Director of Biocon Biologics Ltd, said.
Bmab 1200 … $10.85 billion.
Notably, Biocon had earlier announced a settlement …
-
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
29 Aug 2024 06:31 GMT
… this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen … to regulatory approval.
About Biocon Biologics Limited:
Biocon Biologics Ltd. (BBL), … while improving healthcare outcomes.
Biocon Biologics has commercialized eight …
-
Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan
29 Aug 2024 06:22 GMT
… company, a subsidiary of Biocon Ltd, has inked a … settlement agreement, Biocon Biologics has resolved patent disputes with Janssen … under review, it added.
Biocon Biologics had earlier announced … ) to global markets," Biocon Biologics CEO & Managing …
About
© 1995-2024